key: cord-0945177-e6tf1qn4
authors: Tchouaket Nguemeleu, Eric; Beogo, Idrissa; Sia, Drissa; Kilpatrick, Kelley; Séguin, Catherine; Baillot, Aurélie; Jabbour, Mira; Parisien, Natasha; Robins, Stephanie; Boivin, Sandra
title: Economic analysis of healthcare-associated infection prevention and control interventions in medical and surgical units: Systematic review using a discounting approach
date: 2020-07-08
journal: J Hosp Infect
DOI: 10.1016/j.jhin.2020.07.004
sha: 2c9e454b32d8b75719fb80effc6e2655026a1362
doc_id: 945177
cord_uid: e6tf1qn4

BACKGROUND: Nosocomial or healthcare-associated infections (HCAIs) are associated with a financial burden that affects both patients and healthcare institutions worldwide. The clinical best care practices (CBPs) of hand hygiene, hygiene and sanitation, screening, and basic and additional precautions aim to reduce this burden. The COVID-19 pandemic has confirmed these four CBPs are critically important prevention practices that limit the spread of HCAIs. AIM: This paper conducted a systematic review of economic evaluations related to these four CBPs using a discounting approach. METHODS: We searched for articles published between 2000 and 2019. We included economic evaluations of infection prevention and control of Clostridioides difficile-associated diarrhoea, meticillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and carbapenem-resistant Gram-negative bacilli. Results were analyzed with: cost-minimization, cost-effectiveness, cost-utility, cost-benefit and cost-consequence analyses. Articles were assessed for quality. RESULTS: A total of 11 898 articles were screened and seven were included. Most studies (4/7) were of overall moderate quality. All studies demonstrated cost effectiveness of CBPs. The average yearly net cost savings from the CBPs ranged from $252 847 (2019 $CAD) to $1 691 823 depending on the rate of discount (3% and 8%). The average incremental benefit cost ratio of CBPs varied from 2.48 to 7.66. CONCLUSION: In order to make efficient use of resources and maximize health benefits, ongoing research in the economic evaluation of infection control should be carried out to support evidence-based healthcare policy decisions.

between economic benefits and costs in terms of net gains or losses is 202 estimated. In this approach, an examined intervention will be compared against 203 the status quo to determine its return on investment or profitability. Finally, a CCA 204 is based on a tabular presentation of costs and consequences, leaving benefits 205 (outcomes) in their natural units. Once the cost valuation has been completed, a 206 list is drawn up of all possible intervention outcomes and the choice can be made 207 to value certain potential outcomes. 208

Conducting an economic analysis of HCAI prevention and control therefore 209 involves examining issues of quality management, prevention, and care safety. 210

Thus, as Finkler (1993 Finkler ( , 1996 

The interventions targeted by this review were based on the study's theoretical 238 framework (Supplementary File I). The four major types of intervention (hand 239 hygiene, hygiene and sanitation, screening, and additional precautions) related to 240 CBPs in HCAI prevention and control programmes were analyzed. Studies that 241 investigated any practice other than the four CBPs were excluded. 242

In regard to Comparators and Designs, this review included: randomized clinical 244 trials (RCTs), quasi-experimental, case-control, cohort, retrospective, 245 prospective, longitudinal, and cross-sectional studies. Any review or study that 246 was purely clinical, or a technological assessment, or based solely on 247 mathematical and statistical modelling was excluded. We also excluded 248 pharmacoeconomic studies (i.e., those that compared the value of therapeutic or 249 preventative drug interventions). 250

Outcomes included all quantitative studies using CMA, CEA, CUA, CBA, and 252 CCA, as well as those combining any of these types of analyses. We considered 253 healthcare facilities for the analytical frame and one year as the time horizon. 254

Only studies that assessed the cost-effectiveness analysis of the four CBPs were 255 included. Measurements of cost-effectiveness were reported as: net cost savings 256 decision. An article was rejected if at least two of the three reviewers consider it 293 ineligible. After screening, all the records with a conflict were reviewed (by ET 294 and IB), and an agreement on rejection or acceptance was made. The full text of 295 the selected articles was reviewed for this purpose. Finally, two PCI programme 296 specialists (SB and NP) assessed the content to ascertain whether the final 297 selected studies were technically sound and fell into HCAI prevention and control 298 programs as defined by our four pathogens and CBPs. 299

For data extraction, an Excel spreadsheet built by the research team and based 301 on Consolidated Health Economic Evaluation Reporting Standards 302 (CHEERS)(43) was used to extract the following information: authors, year of 303 publication, title and abstract, objective of the study, country, type of clinical unit, 304 design, type of economic evaluation, sample size, population size, currency and 305 adjustment year, time horizon, outcomes related to incremental cost, and funding 306 sources. The extraction was made by one reviewer (IB) and the principal 307 investigator (ET) validated all data. 308

The quality of included articles was assessed using three tools commonly used in 310 economic evaluations. We used these tools because each assesses the 311 economic evaluation components that may differ within, and between, articles. 312

By using them simultaneously we ensured the robustness of our assessment of 313 quality analysis. We first used the audit guidelines for economic evaluation 314 studies recommended by the Scottish Intercollegiate Guidelines (SIGN)(44). As with the extraction of articles, two reviewers (ET and IB) independently 322 assessed the quality of the articles. If a consensus was not reached, a third 323 reviewer (SD) arbitrated. Studies were classified as "high quality" if the average 324 score across quality assessment tools was at least 80 %; "moderate quality" if 325 the average score was between 60% and 79.9% and "low quality" if below 60% 326

. 327

For each type of intervention, net cost savings, cost-effectiveness ratios, cost-329 utility ratios, and cost-benefit ratios were tabulated. The year of calculation and 330 the currency used were also indicated. Based on the exchange rate, all 331 currencies were converted to Canadian dollars ($CAD) of the same benchmark 332

year. Using the discount rates of 3%, 5%, and 8% recommended by An overview of the reviewed studies using the CHEERS checklist is provided in 404 Table IIIa and Table IIIb . 405

Economic evaluation design 406 Table IV Table V. Tables VI-VIII summarize When screening for MRSA, the cost for each isolation day avoided using 507 Chromogenic agar, IDI and GeneXpert in "nare only" would be between 71.3 and 508 120.1 $CAD. The cost for each isolation day avoided using Chromogenic agar, 509 IDI and GeneXpert in all body sites would between $290.0 and $372.9 $CAD. 510

These are based on the discount rates of 3% and 8% respectively. 511

For every dollar invested in the hand hygiene campaign, we would save between 513 9.3 and 18.1 $CAD based on the discount rates of 3% and 8% respectively. 514

For every dollar invested in the prevention and control programme based on 515 screening with nasal swabs, additional contact isolation precautions, basic 516 precautions with gloves and gowns, eradication treatment, nasal mupirocin and 517 chlorhexidine body wash we would save between 2.5 and 3.6 $CAD. 518

For every dollar invested in the VRE prevention and control programme using 519 screening, basic precautions with gloves and gowns, patient education by 520 nurses, and antimicrobial control using nurse monitoring, we would save between 521 6.7 and 20.9 $CAD based on the discount rates of 3% and 8% respectively. 522

Finally, for every dollar invested in the MRSA search and destroy intervention 523 using screening, additional precautions isolation, basic precautions with gowns, 524 gloves, masks, cleaning and sanitation, contact tracing, treatment of carriers, 525 closure of wards and outbreak situation, we had savings between 4.1 and 7.7 526 $CAD based on the discount rates of 3% and 8% respectively. 527

Summary of evidence 529

The objective of this study was to conduct a systematic review of the literature to 530 consolidate the evidence, using a discounting approach, of the economic 531 evaluation of any of the four CBPs (hand hygiene, hygiene and sanitation of 532 surfaces and equipment, admission screening, and additional precautions) 533 related to HCAI prevention and control interventions. This review allowed our 534 team to measure the net cost savings or incremental cost benefit ratio of these 535 practices for the prevention and control of the four most monitored pathogens 536 (CDAD, MRSA, VRE, and CR-GNB), in medical and surgical units in Canadian 537 hospitals. 538

To the best of our knowledge, this is the first systematic review that focuses on 539 economic evaluations using a discounting approach of these four CBPs 540 simultaneously as they relate to the four pathogens investigated, within the 541 context of HCAI prevention and control interventions in medical and surgical 542 units. 543

Our systematic review searched scientific and grey literature with a large number 544 (eight) of databases. It identified seven studies that evaluated the net cost 545 savings or incremental cost benefit ratios associated with at least one of the 546 CBPs related to two (MSRA and VRE) prevention and control interventions. 547

Hand hygiene, contact isolation precautions, screening, and combinations of 548 hand hygiene, cleaning and sanitation, contact isolation precautions, basic 549 precautions with gloves, gowns, marks and screening were cost-effective. 550

To summarize, first, a hand hygiene MRSA prevention campaign could save 551 more than 1.2 million $CAD annually, and up to 2.5 million $CAD depending to 552 the proportion of the reduction of MRSA. Also, for every one dollar invested in the 553 hand hygiene campaign, we would save more than 9.3 $CAD, and that translates 554 into more than 18 $CAD based on the discount rates in medical and surgical 555 hospital units. 556

Second, MRSA screening using PCR would provide an annual net cost savings 557 of more than 870 000 $CAD, and could reach 1.7 million $CAD. For every dollar 558 invested in the MRSA screening using PCR, two studies show we could save 559 more than 2.9 $CAD and possibly more than 6.5 $CAD in medical and surgical 560 hospital units. Moreover, the MRSA screening intervention could permit 561 healthcare facilities/systems to save more than 290 $CAD per isolation day and 562 could surpass 372 $CAD per isolation day depending on the type of test and the 563 sampling site (e.g. "nare only" testing versus whole body screening). 564

Third, MRSA contact precautions could provide minimum savings of 42 000 565 $CAD. This could reach more than 564 000 $CAD if the MRSA contact 566 precautions intervention is that of using only gloves. 567

Fourth, an MRSA prevention and control programme using a combination of 568 screening with a nasal swab, additional contact isolation precautions, basic 569 precautions with gloves and gowns, eradication treatment, nasal mupirocin and 570 chlorhexidine body wash would provide an annual net cost savings more than 571 252 000 $CAD, and could reach 369 000 $CAD. Also, for every dollar invested in 572 this programme, we could save more than 2.5 $CAD. 573 Savings could be 627 used to strengthen medical human resources (physicians, nurses, nursing 628 assistants, patient attendants, and hygiene and sanitation workers), material 629 resources (gloves, gowns, masks), equipment and products (hydro-alcoholic 630 solutions, hydrogen peroxide), as well as information resources (web/mobile 631 applications for case detection) dedicated to infection prevention and control 632

programmes. 633

Care providers should take better precautions before, during and after every care 634 intervention by practicing good hand hygiene, thorough hygiene and sanitation, 635 taking precautionary measures and respecting any required additional 636 precautions. Health administrators must reinforce prevention and control 637 procedures in their organization as these processes ultimately lead to cost 638 savings. They could systematically assess the cost-effectiveness of CBPs to 639 better administer HCAI prevention and control, and encourage the effective 640 application of infection control guidelines (47, 60) . 641

Research results should be shared with patients and their families so that they 642 can be made aware of the financial and human repercussions and benefits 643 associated with infection prevention. They could thus better collaborate in 644 infection prevention actions to ensure their own or their loved one's health and 645 safety during hospitalization. 646

Finally, as seen with the COVID-19 pandemic, hand hygiene, cleaning and 647 sanitation, screening, and basic precautions with gloves, gowns, masks, and 648 additional isolation precautions are critically important prevention strategies to 649 limit the spread of disease and protect patients and healthcare providers. Our 650 study highlights its importance from an economic perspective. These results 651 would be useful for comparison between OECD countries in terms of CBPs 652 related to HCAI prevention and control. Future research should improve the 653 quantity and quality of economic evaluations of CBPs related to HCAI prevention 654 and control to provide relevant and timely information to healthcare policy 655 makers. This investment in the assessment of cost-effectiveness would empower 656 healthcare policy makers to make the most efficient use of valuable, shared and 657 limited health resources in order to achieve the best health outcomes. 

Acknowledgements: The authors would like to thank the FRQS for their financial 661 support. They thank all the staff and managers at the public health department of 662 the Laurentian Region and the nursing department of the Saguenay-Lac-Saint-663

Jean region. The authors are grateful to Marie-Claude Laferrière

CDC/NHSN surveillance definition of 714 health care-associated infection and criteria for specific types of infections in the 715 acute care setting

Extra length of stay and costs because of health care-associated infections at 718 a German university hospital

Health 720 care costs associated with hospital acquired complications in patients with 721 chronic kidney disease

Burden of Six Healthcare-Associated Infections on European Population 724 Health: Estimating Incidence-Based Disability-Adjusted Life Years through a 725 Population Prevalence-Based Modelling Study

Public Health Agency of Canada. The Chief Public Health Officer's Report 728 on the State of Public Health in Canada 2013 -Infectious disease -The never-729 ending threat

Canadian Institute for Health Information, Canadian 731 Patient Safety Institute. Measuring Patient Harm in Canadian Hospitals, What 732 can be done to improve patient safety

L'hygiène et autres 734 mesures de prévention des infections associées aux bactéries multirésistantes: 735 document synthèse. Montreal, QC: Institut national de santé publique du 736 Québec. 2014. 737 8. Public Health Agency of Canada. Routine practices and additional 738 precautions for preventing the transmission of infection in healthcare settings

Institut national de santé publique du Québec. Institut national de santé 741 publique du Québec. Campagne québécoise des soins sécuritaires -volet 742 prévention et contrôle des infections. Montreal, QC: INSPQ

Canadian Patient Safety Institute. New approach to controlling superbugs 744

Safer Healthcare Now!

Using care bundles to improve 746 health care quality. HI Innovation Series white paper. 2012;Cambridge, MA: 747 Institute for Healthcare Improvement. 748 12. First Affiliated Hospital of Zhejiang University. Handbook of COVID-19 749 Prevention and Treatment2020

Health Care-Associated Infections: A Meta-analysis of Costs and Financial 753 Impact on the US Health Care System

Economic burden of 755 antibiotic resistance in ESKAPE organisms: a systematic review

Economic 758 healthcare costs of Clostridium difficile infection: a systematic review

Agence d'évaluation des technologies et des modes d'intervention en 761 santé

Cost-benefit of 765 infection control interventions targeting methicillin-resistant Staphylococcus 766 aureus in hospitals: systematic review

Economic evaluation of vancomycin-resistant enterococci (VRE) 769 control practices: a systematic review

Systematic review of economic analyses 771 of health care-associated infections

A systematic audit of economic evidence 773 linking nosocomial infections and infection control interventions: 1990-2000. Am 774

Economic evaluation to inform health care 776 decision-making: promise, pitfalls and a proposal for an alternative path

Crossing the quality chasm: a new health system for 779 the 21st century

Using the Results of Economic Evaluations of 781 Public Health Interventions: Challenges and Proposals

The 784 economic value of Quebec's water fluoridation program

UK: Oxford 788 University Press; 2015. 789 26. Public Health Agency of Canada. Routine practices and additional 790 precautions for preventing the transmission of infection in healthcare settings

World Health Organization. WHO Guidelines on hand hygiene in health 793 care, first global patient safety challenge clean care is safer care

Groupe de travail en hygiène et salubrité. Guide de gestion intégrée de la 800 qualité en hygiène et salubrité. Gouvernement du Québec, Ministère de la Santé 801 et des Services sociaux

Groupe Hygiène et salubrité au regard de la lutte aux infections 803 nosocomiales. Lignes directrices en hygiène et salubrité : analyse et 804 concertation. Québec, QC: 2006. 805 31. Institut national de la santé publique du Québec. Surveillance provinciale 806 des bactériémies à Staphylococcus au Québec: protocole. Montreal, QC2018. 807 32. Institut national de la santé publique du Québec

Institut national de la santé publique du Québec. Surveillance des 811 infections à bacilles Gram négatif producteurs de carbapénémases au Québec: 812 protocole. Montreal, QC:2017. 813 34. Public Health Agency Of Canada

Comité sur les infections nosocomiales du Québec. Précisions sur la 819 gestion d'une éclosion majeure de grippe saisonnière nosocomiale en milieux de 820 soins: lignes directrices. Montreal, QC

The 822 economics of patient safety in acute care

Total quality management: measuring costs of quality

Measuring the costs of quality

Health care 828 system performance of 27 OECD countries. The International Journal of Health 829 Planning and Management

834 Preferred reporting items for systematic review and meta-analysis protocols 835 (PRISMA-P)

Rayyan-a web and mobile app for systematic reviews

Consolidated Health Economic Evaluation Reporting Standards 840 (CHEERS)-Explanation and Elaboration:A Report of the ISPOR Health 841 Economic Evaluation Publication Guidelines Good Reporting Practices Task 842 Force

Scottish Intercollegiate Guidelines Network. SIGN 50: a guideline 844 developer's handbook. Edinburgh: SIGN

Cochrane Handbook for Systematic Reviews of 846 Interventions Version 6

Taux d'actualisation pour l'évaluation des 848 investissements publics au Québec. Montreal, QC: Centre for Interuniversity 849 Research and Analysis on Organizations

The economic burden of nurse-851 sensitive adverse events in 22 medical-surgical units: retrospective and matching 852 analysis

856 49. van Rijen MM, Kluytmans JA. Costs and benefits of the MRSA Search and 857 Destroy policy in a Dutch hospital

Costs and savings associated with infection control measures that reduced 861 transmission of vancomycin-resistant enterococci in an endemic setting

Staphylococcus aureus carriage at different anatomical sites: costs and benefits 866 of less extensive screening regimens. Clinical microbiology and infection : the 867 official publication of the European Society of Clinical Microbiology and Infectious 868 Diseases

Impact of a 870 hand hygiene campaign in a tertiary hospital in South Korea on the rate of 871 hospital-onset methicillin-resistant Staphylococcus aureus bacteremia and 872 economic evaluation of the campaign

Cost Analysis of 874 an Intervention to Prevent Methicillin-Resistant Staphylococcus Aureus (MRSA)

Financial 877 implications of plans to combat methicillin-resistant Staphylococcus aureus 878 (MRSA) in an orthopaedic department

Challenges Faced in Transferring Economic Evaluations to Middle 881 Income Countries

Changing 883 Health Technology Assessment Paradigms? Int J Technol Assess Health Care

Clostridium difficile Infection: An 886 Epidemiology Update

A nationwide study of comorbidity and risk of reinfection after Staphylococcus 889 aureus bacteraemia

Economic evaluation across the four 891 faces of prevention: A Canadian perspective

The occurrence 895 of adverse events potentially attributable to nursing care in medical units: cross 896 sectional record review